 |
49 Diseases |  |
64 Trials |
|
64 Trials |  |
670 News |  |
| «1234567891011» |
- | Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: NCI-2014-01707: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 21, 2023
P2, N=6, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=40 --> 6 | Trial completion date: Jun 2023 --> Feb 2023 | Trial primary completion date: Jun 2023 --> Feb 2023
- | Calquence (acalabrutinib) / AstraZeneca
Trial completion date, Trial primary completion date: Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Sep 15, 2023
P2, N=45, Recruiting, Sponsor: Academic and Community Cancer Research United
Active, not recruiting --> Completed | N=40 --> 6 | Trial completion date: Jun 2023 --> Feb 2023 | Trial primary completion date: Jun 2023 --> Feb 2023 Trial completion date: Aug 2025 --> Aug 2028 | Trial primary completion date: Aug 2024 --> Sep 2025
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion date: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2023
P3, N=218, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Aug 2025 --> Aug 2028 | Trial primary completion date: Aug 2024 --> Sep 2025 Trial completion date: Jul 2023 --> Jun 2024
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Enrollment closed, Enrollment change, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Sep 6, 2023
P2, N=7, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jul 2023 --> Jun 2024 Suspended --> Active, not recruiting | N=60 --> 7
- | nelarabine / Generic mfg.
Trial completion date, Trial primary completion date: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Sep 5, 2023
P2, N=160, Recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Active, not recruiting | N=60 --> 7 Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
- | abiraterone acetate / Generic mfg.
Biomarker, Phase classification, Enrollment change, Trial completion date, Trial primary completion date: Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms (clinicaltrials.gov) - Aug 31, 2023
P2/3, N=600, Active, not recruiting, Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024 Phase classification: P1 --> P2/3 | N=20 --> 600 | Trial completion date: Oct 2023 --> May 2024 | Trial primary completion date: Oct 2023 --> May 2024
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Enrollment open: Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. (clinicaltrials.gov) - Aug 29, 2023
P1, N=50, Recruiting, Sponsor: University of Chicago
Phase classification: P1 --> P2/3 | N=20 --> 600 | Trial completion date: Oct 2023 --> May 2024 | Trial primary completion date: Oct 2023 --> May 2024 Not yet recruiting --> Recruiting
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Trial completion date, Trial primary completion date: Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. (clinicaltrials.gov) - Aug 28, 2023
P1, N=50, Not yet recruiting, Sponsor: University of Chicago
Not yet recruiting --> Recruiting Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- | revumenib (SNDX-5613) / Syndax Pharma
Trial initiation date, Combination therapy: A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (clinicaltrials.gov) - Aug 15, 2023
P2, N=78, Not yet recruiting, Sponsor: Children's Oncology Group
Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 Initiation date: Jun 2023 --> Oct 2023
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Metastases: c15-148: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 14, 2023
P1/2, N=37, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Initiation date: Jun 2023 --> Oct 2023 Trial completion date: Aug 2025 --> Dec 2023
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial completion date, Trial primary completion date: NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 4, 2023
P1, N=6, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Aug 2025 --> Dec 2023 Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024
- | Journal: Expanded table: Some drugs for inflammatory bowel disease. (Pubmed Central) - Jul 11, 2023
Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024 No abstract available
- | Journal: Drugs for inflammatory bowel disease. (Pubmed Central) - Jul 11, 2023
No abstract available No abstract available
- | Akeega (abiraterone/niraparib) / J&J, Zejula (niraparib) / GSK, J&J
Enrollment open, Metastases: CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations (clinicaltrials.gov) - Jul 10, 2023
P2, N=30, Recruiting, Sponsor: Mayo Clinic
No abstract available Not yet recruiting --> Recruiting
- || prednisone delayed-release tablet / Generic mfg.
Claro, claro… rayos saliendo del arca de la alianza son más verosímiles (Twitter) - Jul 8, 2023
- || Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion, Trial completion date: Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 6, 2023
P1, N=24, Completed, Sponsor: University of Washington
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Oct 2027 --> Jun 2023
- | prednisone delayed-release tablet / Generic mfg.
Qué son rayos C (Twitter) - Jun 25, 2023
- || prednisone delayed-release tablet / Generic mfg.
Protege a tus pequeños en esta época de #CalorExtremo ⚠️ Los bebés son más sensibles a los rayos UV, por lo que nuestra Dermatóloga Pediatra @MTollefsonMD y @heraldodemexico han preparado algunos tips para prevenir daños en sus pieles. Consúltalos en: https://t.co/WuW51nrFBX (Twitter) - Jun 23, 2023
- | Rinvoq (upadacitinib) / AbbVie
Trial initiation date: A Trial for Acute Severe Ulcerative Colitis (clinicaltrials.gov) - Jun 23, 2023
P4, N=162, Not yet recruiting, Sponsor: Berinstein, Jeffrey
Active, not recruiting --> Completed | Trial completion date: Oct 2027 --> Jun 2023 Initiation date: May 2023 --> Aug 2023
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion date: P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov) - Jun 23, 2023
P2, N=48, Active, not recruiting, Sponsor: City of Hope Medical Center
Initiation date: May 2023 --> Aug 2023 Trial completion date: May 2023 --> Dec 2023
- || prednisone delayed-release tablet / Generic mfg.
Llama la atención cuándo viene de un sindicato que denuncia a los técnicos de rayos para que no administren contraste endovenoso y demás. Y que conste que yo estoy en contra de las demandas de sindicatos médicos en el mismo sentido. (Twitter) - Jun 17, 2023
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial, Combination therapy, Metastases: Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (clinicaltrials.gov) - Jun 9, 2023
P1/2, N=16, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
Trial suspension, Combination therapy: Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jun 8, 2023
P1, N=24, Suspended, Sponsor: Yazeed Sawalha
Trial completion date: May 2023 --> Dec 2023 Recruiting --> Suspended
- || Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma, Rituxan (rituximab) / Roche
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jun 7, 2023
P2, N=24, Recruiting, Sponsor: Joseph Tuscano
Recruiting --> Suspended Not yet recruiting --> Recruiting | Trial completion date: Aug 2027 --> Feb 2028 | Initiation date: Dec 2022 --> May 2023 | Trial primary completion date: Aug 2025 --> Feb 2026
- ||| itacitinib (INCB039110) / Incyte
Trial completion date, Trial primary completion date: GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Jun 6, 2023
P2/3, N=155, Active, not recruiting, Sponsor: Incyte Corporation
Not yet recruiting --> Recruiting | Trial completion date: Aug 2027 --> Feb 2028 | Initiation date: Dec 2022 --> May 2023 | Trial primary completion date: Aug 2025 --> Feb 2026 Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, Immuno-oncology: AHOD2131: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (clinicaltrials.gov) - Jun 5, 2023
P3, N=1875, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023 Trial completion date: Jun 2030 --> Apr 2031 | Trial primary completion date: Jun 2030 --> Apr 2031
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 2, 2023
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2030 --> Apr 2031 | Trial primary completion date: Jun 2030 --> Apr 2031 Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2023 --> Dec 2023
- | lenalidomide / Generic mfg.
Trial completion date, Combination therapy, IO biomarker: Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL) (clinicaltrials.gov) - May 31, 2023
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2023 --> Dec 2023 Trial completion date: Dec 2025 --> Dec 2026
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Trial completion date: AHOD1331: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (clinicaltrials.gov) - May 31, 2023
P3, N=600, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2025 --> Dec 2026 Trial completion date: Jan 2023 --> Dec 2029
- | Remicade (infliximab) / J&J
Trial completion date, Trial primary completion date, IO biomarker: ECOG-ACRIN-EAQ172: Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis (clinicaltrials.gov) - May 25, 2023
P2, N=36, Recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
Trial completion date: Jan 2023 --> Dec 2029 Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
- | lenalidomide / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy, IO biomarker: Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL) (clinicaltrials.gov) - May 25, 2023
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025 Trial completion date: Jun 2023 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Dec 2025
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - May 25, 2023
P3, N=6720, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2023 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Dec 2025 Trial completion date: Dec 2029 --> Mar 2030 | Trial primary completion date: Dec 2029 --> Mar 2030
- |||||| prednisone delayed-release tablet / Generic mfg.
Clinical: El melanoma es el cáncer de piel más grave y puede ser causado por demasiada exposición a los rayos ultravioleta (UV) del sol. Hoy, Día Mundial de Concientización sobre el Melanoma, escucha al Dr. Javier Soteldo (@JAVIERSOTELDOC) especialista del Hospital de Clínicas Caracas. (Twitter) - May 23, 2023
- | Rinvoq (upadacitinib) / AbbVie
New P4 trial: A Trial for Acute Severe Ulcerative Colitis (clinicaltrials.gov) - May 22, 2023
P4, N=162, Not yet recruiting, Sponsor: Berinstein, Jeffrey
- | Polivy (polatuzumab vedotin-piiq) / Roche, parsaclisib (INCB50465) / Incyte, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - May 18, 2023
P1, N=50, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Dec 2029 --> Mar 2030 | Trial primary completion date: Dec 2029 --> Mar 2030 Recruiting --> Active, not recruiting
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS
Enrollment open, Immuno-oncology: AHOD2131: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (clinicaltrials.gov) - May 15, 2023
P3, N=1875, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Calquence (acalabrutinib) / AstraZeneca
Trial completion date, Trial primary completion date: Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - May 12, 2023
P2, N=45, Recruiting, Sponsor: Academic and Community Cancer Research United
Not yet recruiting --> Recruiting Trial completion date: Aug 2028 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2024
- | mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Enrollment change, Trial withdrawal: Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS) (clinicaltrials.gov) - May 6, 2023
P2, N=0, Withdrawn, Sponsor: University of Maryland, Baltimore
Trial completion date: Aug 2028 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2024 N=30 --> 0 | Not yet recruiting --> Withdrawn
- ||| prednisone delayed-release tablet / Generic mfg.
Tal vez porque los rayos X son comprobados cancerígeno, y no se debe abusar de las radiografías si no son necesarias. Debería ser solo después de evaluación de riesgo tomada por un médico. Ya hay investigaciones sobre esto (Twitter) - May 3, 2023
- ||| prednisone delayed-release tablet / Generic mfg.
La molécula del ADN fue descubierta en 1869 por Friedrich Miescher, el 25 de abril de 1953 James Watson y Francis Crick publican su artículo donde describen la estructura de esta molécula, gracias a la fotografía 51 tomada por Rosalind Franklin mediante difracción de rayos X (Twitter) - Apr 25, 2023
- | Akeega (abiraterone/niraparib) / J&J, Zejula (niraparib) / GSK, J&J
Trial initiation date, Metastases: CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations (clinicaltrials.gov) - Apr 25, 2023
P2, N=30, Not yet recruiting, Sponsor: Mayo Clinic
N=30 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Mar 2023 --> Jun 2023
- |||| prednisone delayed-release tablet / Generic mfg.
Amazing talk on Ultra Hypofractionation in Breast Cancer from @Monthy_A for Rayos Contra Cancer Hypofractionation Curriculum for LATAM ⚡️🤞🏻 RT provides the lowest NNT and only in 5 days🤘MORE TO COME !⚡️☢️@CancerRayos @BenLiMD @davidamperez86 @acro_colombia @Elekta @somera_mx (Twitter) - Apr 22, 2023
- ||| prednisone delayed-release tablet / Generic mfg.
Inspiradora presentación del maestro Ángel Montero Luis @Monthy_A para Rayos Contra el Cáncer @CancerRayos sobre Ultra hipofraccionamiento en cáncer de mama… Esto SI QUE ES Radioterapia ☢️☢️ (Twitter) - Apr 22, 2023
- ||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Enrollment closed, Enrollment change, Metastases: Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer (clinicaltrials.gov) - Apr 19, 2023
P2, N=7, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Initiation date: Mar 2023 --> Jun 2023 Recruiting --> Active, not recruiting | N=76 --> 7
- ||| Sarclisa (isatuximab-irfc) / Sanofi
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2023
P1/2, N=15, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting | N=76 --> 7 Recruiting --> Active, not recruiting | N=37 --> 15 | Trial completion date: Oct 2029 --> Dec 2023 | Trial primary completion date: Oct 2024 --> Mar 2023
- | Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 5, 2023
P1, N=24, Recruiting, Sponsor: Yazeed Sawalha
Recruiting --> Active, not recruiting | N=37 --> 15 | Trial completion date: Oct 2029 --> Dec 2023 | Trial primary completion date: Oct 2024 --> Mar 2023 Trial primary completion date: Dec 2022 --> Dec 2023
- | Onureg (azacitidine oral) / BMS
Enrollment open: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Apr 5, 2023
P2/3, N=422, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2022 --> Dec 2023 Suspended --> Recruiting
- | Monjuvi (tafasitamab-cxix) / MorphoSys, Xencor, Incyte, Specialised Therap, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion date, Trial primary completion date: Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 4, 2023
P2, N=30, Recruiting, Sponsor: University of Washington
Suspended --> Recruiting Trial completion date: Jun 2027 --> Sep 2030 | Trial primary completion date: Jun 2025 --> Sep 2025
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment change, Trial completion date, Trial primary completion date, Checkpoint inhibition, Checkpoint block, Metastases: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (clinicaltrials.gov) - Mar 30, 2023
P1, N=10, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2027 --> Sep 2030 | Trial primary completion date: Jun 2025 --> Sep 2025 N=16 --> 10 | Trial completion date: May 2023 --> Mar 2024 | Trial primary completion date: May 2023 --> Oct 2022
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment closed, Metastases: CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) - Mar 28, 2023
P1, N=12, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
N=16 --> 10 | Trial completion date: May 2023 --> Mar 2024 | Trial primary completion date: May 2023 --> Oct 2022 Recruiting --> Active, not recruiting